The ACPHS Research Commons collects in one space the digitised research and scholarship generated by the college’s faculty, students, and staff.
Learn more about ACPHS and the Research Commons.
Recent Submissions
Item Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022.(BMC Infectious Diseases, 2025-04-17)Background: Epidemiological data for United States (US) hospitals regarding the burden of Acinetobacter baumannii and carbapenem-resistant A. baumannii (CRAB) are scarce; thus, this study aimed to describe the incidence of A. baumannii and CRAB across US hospitals between January 1, 2018 and December 31, 2022.Item ACPHS 2025 Annual Research Symposium(2025-04-03)Item Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network.(Journal of Oncology Pharmacy Practice, 2025-04-01)Purpose: The time to complete oncology pharmacist tasks is needed to determine workload and productivity. The Hematology/Oncology Pharmacy Association (HOPA) and the Hematology/Oncology Practice and Research Network (PRN) of the American College of Clinical Pharmacy (ACCP) partnered with the aim of establishing consensus on the time required to complete oncology pharmacy tasks. Methods: Fifteen patient care tasks and 9 non-patient care tasks, commonly completed by oncology pharmacists were each assigned an average amount of time to be completed. This list was then converted into 24 statements and the Delphi survey method was utilized with an expert panel to arrive at consensus between December 2023 and February 2024. Consensus was defined as at least 75% agreement. The complete manuscript was endorsed by HOPA and ACCP Hematology/Oncology PRN. Results: Thirty-three pharmacist-experts agreed to participate in this survey with all participating in round 1, and 29 (87.9%) participating in round 2. In round 1, 9 tasks achieved consensus, with 7 of these being classified as patient care associated. Seven statements reaching 65% but less than 75% agreement were deemed to reach borderline consensus. Eight statements failed to achieve at least 65% agreement and were modified based on respondent feedback. In round 2, 15 statements were included with all achieving consensus. At the completion of round 2, all 24 statements reached consensus, and the survey was deemed complete. Conclusion: This project produced the first comprehensive consensus statements for the average time for a US-based oncology pharmacist to complete common patient and non-patient care-related tasks.Item Combination Effects of Aminolevulinic Acid and Mycophenolic Acid on Hacat Cell Proliferation and Inhibition of Inosine Monophosphate Dehydrogenase.(Molecules, 2025-03-18)Derivatives of mycophenolic acid (MPA) and 5-aminolevulinic acid photodynamic therapy (ALA-PDT) have been used separately to treat psoriasis, a chronic, inflammatory skin disease that is characterized by the unregulated hyperproliferation of epidermal keratinocytes and a T-cell-mediated immune response. However, the combination of these two therapies has not previously been explored. This study investigated the in vitro effects of combining MPA with ALA-PDT to suppress keratinocytes and the in vitro inhibition of inosine monophosphate dehydrogenase, a key enzyme. The effects of ALA, MPA, and their combination on protoporphyrin IX (PpIX) generation and cell viability in HaCaT cells, as well as the inhibition of IMPDH, were evaluated. Treatment of HaCaT cells with ALA, MPA, and their 1:1 molar combination showed that ALA alone induced PpIX production, with concentrations increasing from 5.25 ng/mL at 10 μM to 157.5 ng/mL at 1 mM. MPA did not increase PpIX on its own but had a modest synergistic effect with ALA at low concentrations (10 μM and 50 μM). The impact of blue light irradiation (465 nm) on cell viability was also assessed, revealing that ALA and ALA + MPA treatment led to significant reductions in HaCaT cell viability at higher concentrations (500 μM-1 mM), while MPA alone with blue light irradiation showed no cytotoxicity. The reduction in skin cell viability was enhanced when ALA was combined with MPA. Additionally, MPA effectively inhibited IMPDH activity in a dose-dependent manner, with 94-96% inhibition at concentrations of 100 μM and above. Interestingly, ALA weakly inhibited IMPDH, with a peak inhibition of 46% at 5 μM. At higher ALA concentrations, its inhibitory effect diminished, and it interfered with the potency of MPA's IMPDH2 inhibition, suggesting that ALA could modulate MPA's therapeutic action. These findings suggest that the combination of MPA with ALA-PDT may be a viable new treatment for psoriasis.Item Adults’ perceptions of children’s ground rule applications during investigative interviews(Psychology, Crime & Law, 2025-02-21)Ground rules are a recommended portion of investigative interviews with children. The current study examined how adults perceive children’s application of the I Don’t Understand (IDU) or I Don’t Know (IDK) rules during investigative interviews. Jury-eligible adults (N = 716) viewed a transcript of a child alleging sexual abuse in a 2 (Child Age: 6 v. 10) × 2 (Rule Applied: IDU v. IDK) × 2 (Rule Application Frequency: 1-time v. 6-times) design. Adults perceived the child who applied a rule 1 time as more credible, less likely to have intentionally lied, and more likely to have understood what her statements would be used for than the child who applied a rule 6 times. Child age and type of rule applied had more limited effects. Results have implications for those who interview children, design interview interventions, and provide expert testimony regarding child witnesses.
Communities in Research Commons @ ACPHS
Select a community to browse its collections.